Skip to main content
Premium Trial:

Request an Annual Quote

Compugen, Premier Biosoft

Premium
Compugen this week introduced the Viral Peptides Discovery Platform for the identification of peptides from viral genomes for potential therapeutic use against inflammatory and immune-related diseases.
 
The company said the platform has been validated and led to the discovery of two novel viral peptides that have demonstrated the ability to suppress inflammatory response in in vitro studies.
 
Using algorithms and in silico tools that predict a large number of potential natural peptides produced by viruses, the platform chooses those peptides that show potential anti-inflammatory activities.
 

 
Premier Biosoft this week launched SimGlycan version 2.6.
 
The MS/MS data analysis software now annotates mass spectra, showing the loss of successive monosaccharides with each peak, “enabling better glycan visualization and outputting publication quality graphics of the results,” the company said in a statement.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.